In COVID-19, severe outcomes have increased levels of pro-inflammatory and anti-inflammatory cytokines and chemokines, such as IL-6, TNF-α, IL-10, CCL2, CCL3, CXCL8, and CXCL10, among others (1, 3, 4). This evidence concerns the gene CCL2 and COVID-19.